Autoantibodies to Joint-Related Peptides Are Associated With Onset of Rheumatoid Arthritis in Presymptomatic Seronegative Individuals - Report - MDSpire

Association of Autoantibodies to Joint-Related Peptides with the Development of Rheumatoid Arthritis in Asymptomatic Seronegative Patients

  • By

  • Outi Sareila

  • Linda Johansson

  • Anders Lundquist

  • Monica Leu Agelii

  • Lei Cheng

  • Yibo He

  • Erik Lönnblom

  • Maria Andersson

  • Jan Kihlberg

  • Anders Esberg

  • Inger Gjertsson

  • Rikard Holmdahl

  • Solbritt Rantapää-Dahlqvist

  • May 27, 2026

Share

Association of Autoantibodies to Joint-Related Peptides with RA Development

Overview

This study investigates the role of serum autoantibodies to joint-related peptides in predicting the development of rheumatoid arthritis (RA) in asymptomatic seronegative patients.

Background

Rheumatoid arthritis (RA) is often preceded by elevated autoantibody levels, making early diagnosis crucial for effective intervention. Current diagnostic methods primarily rely on clinical symptoms and established biomarkers, but a significant proportion of early RA patients are seronegative.

Data Highlights

No numerical data or trial data provided in the source material.

Key Findings

  • Autoantibodies to joint-related peptides may help distinguish seronegative RA from other inflammatory joint diseases.
  • The SeNe test can identify seronegative patients with early RA.
  • Autoantibodies against glucose-6-phosphate isomerase (GPI), type II collagen (COL2), and cartilage oligomeric matrix protein (COMP) are associated with RA diagnosis.
  • Some autoantibodies have been shown to be pathogenic in mouse models of arthritis.
  • Novel biomarkers are essential for recruiting high-risk individuals for clinical studies.

Clinical Implications

Understanding the role of these biomarkers may aid in stratifying patients based on their risk of disease progression.

Conclusion

The study highlights the potential of serum autoantibodies to joint-related peptides as biomarkers for predicting RA development in asymptomatic seronegative patients.

Related Resources & Content

  1. Clinical Rheumatology — Is the Inclusion of Seronegative Rheumatoid Arthritis Patients with Suspected Arthralgia Adequately Addressed in Randomized Clinical Trials?
  2. Clinical Rheumatology — The Role of Autoantibodies and Metalloproteinase Activity in the Early Stages of Arthritis
  3. Clinical Rheumatology — Increasing proportion and more favourable outcomes of seronegative rheumatoid arthritis: analysis of the IORRA cohort from 2000 to 2021
  4. Arthritis & Rheumatology — The Role of IgM Anti-acetylated Protein Antibodies and B Cells in the Origin of Antimodified Protein Autoimmunity in Rheumatoid Arthritis
  5. EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis - PMC
  6. Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial
  7. Autoantibodies as predictors of progression to rheumatoid arthritis: a systematic review and meta-analysis
  8. EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis - PMC
  9. Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial
  10. Autoantibodies as predictors of progression to rheumatoid arthritis: a systematic review and meta-analysis

Original Source(s)

Autoantibodies to Joint-Related Peptides Are Associated With Onset of Rheumatoid Arthritis in Presymptomatic Seronegative Individuals

  • by Outi Sareila, Linda Johansson, Anders Lundquist, Monica Leu Agelii, Lei Cheng, Yibo He, Erik Lönnblom, Maria Andersson, Jan Kihlberg, Anders Esberg, Inger Gjertsson, Rikard Holmdahl, Solbritt Rantapää-Dahlqvist

  • May 27, 2026

Related Content

Does TYK2/JAK1 Show Potential in Inflammatory Diseases?

Investigational inhibitor was not associated with treatment-related serious adverse events and produced biomarker changes consistent with pathway inhibition in healthy volunteers.

Hair Repigmentation Reported With Baricitinib in Canities Subita

A single case suggests a possible benefit, but confounding factors and the off-label setting temper the conclusions.

Tenderness Tracks Ultrasound Findings

Joint tenderness showed broader associations with concurrent ultrasound abnormalities than patient-reported pain among anti-cyclic citrullinated peptide–positive patients without clinical arthritis.